small molecule

ESOMEPRAZOLE MAGNESIUM

Loss of exclusivity—loss of exclusivity

CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand name	ESOMEPRAZOLE MAGNESIUM
Active ingredient	ESOMEPRAZOLE MAGNESIUM
Strength	EQ 20MG BASE/PACKET
Dosage form	FOR SUSPENSION, DELAYED RELEASE
Route	ORAL
Modality	Small molecule
FDA approval	March 2020
Marketing status	RX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.